Please ensure Javascript is enabled for purposes of website accessibility

This Healthcare IT Stock Gets a Gold Medal for Its Game-Changing Software

By Motley Fool Staff - Feb 17, 2018 at 10:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If there were a healthcare Olympics, this company's revolutionary software solution would win it the gold.

With spending on prescription drugs soaring and the number of clinical trials skyrocketing, it's little wonder why healthcare companies are embracing Veeva Systems (VEEV -0.89%) software-as-a-service platform.

In this clip from The Motley Fool's Industry Focus: Healthcare, analyst Kristine Harjes and contributor Todd Campbell explain why more and more companies are turning to Veeva Systems to manage their information and how that's translating into medal-winning sales growth for investors.

A full transcript follows the video.

This video was recorded on Feb. 14, 2018.

Kristine Harjes: And we're back to the Olympics of healthcare with our next competition, health tech. A very broad category, but my gold medal goes to a company called Veeva Systems. They're the dominant SaaS company in the life sciences space, and their value proposition is consolidating legacy IT systems into a single cloud-based system with add-on applications like event management and marketing territory alignment. It's specifically designed for healthcare companies and meeting industry-specific challenges like clinical trial management, regulatory requirements, data collection and more. Their legacy CRM platform is being used by a seriously impressive list of some of the most important and biggest drug makers out there, and their next phase of growth will come from their Veeva Vault, which is a line of products and data management, as well as expansion to beyond just life sciences, which is something that's pretty exciting and was made at the request of companies in other areas who had heard such great things about Veeva that they wanted to be able to use their offerings, even though they're not healthcare companies. From an investing standpoint, I love the predictability of a subscription business. And I also love that it's super sticky. Once you're in their product suite, it's really tough to get out of it and go to a competitor, even if you wanted to. That gives it a super wide moat.

Todd Campbell: That's a really interesting stock. I think it's awesome that you picked it as a gold medalist. I went back and I started looking at this stock, and it's like, wow, no wonder they've had so much revenue growth and so much are earnings growth. Kristine, since 2010, we've gone from 100,000 trials registered on the clinicaltrials.gov website to 266,000 trials.

Harjes: Dang.

Campbell: Just since 2010. So, there's no wonder that that new Veeva Vault that's helping companies manage their clinical trials is enjoying some pretty rapid growth, I think 50% annualized year-over-year just for that piece of the business. So, even if you have some slowdown in that legacy customer relationship management software business, this Veeva Vault is opening up all sorts of new opportunities for them. It's an exciting time for the company.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Veeva Systems Inc. Stock Quote
Veeva Systems Inc.
VEEV
$197.96 (-0.89%) $-1.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.